Skip to main content

Most Likely It'll Mean More Forms

The National Institutes of Health has been trying to crack down on conflicts of interest, to the point that some NIH researchers declined to give talks to industry, says blogger Derek Lowe at In the Pipeline. At the same time, Lowe points out, NIH is moving toward more translational science, which will mean more interactions with industry. "So how will the NIH manage that if the drug industry is seen as contaminating their Purity of Essence?" he asks.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.